Another recent study showed that the results of anti-PD-L1 therapy in tumor-bearing mice was totally abolished in PD-L1-deficient animals, supporting the importance of blocking the PD-1/PD-L1 pathway as an anti-cancer therapeutic approach (142). The gene discussed is PDCD1; the disease is neoplasm.